LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

Search

Palvella Therapeutics Inc

Closed

SectorHealthcare

75.52 1.29

Overview

Share price change

24h

Current

Min

69.57

Max

77.05

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+19.54% upside

Dividends

By Dow Jones

Next Earnings

11 lis 2025

News Sentiment

By Acuity

38%

62%

117 / 373 Ranking in Healthcare

Palvella Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 lis 2025, 23:57 UTC

Earnings

Naver's Third-Quarter Earnings Rose on AI Push

4 lis 2025, 23:10 UTC

Acquisitions, Mergers, Takeovers

Kennedy-Wilson Gets Acquisition Proposal From CEO, Fairfax Financial

4 lis 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 lis 2025, 23:48 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Weakness -- Market Talk

4 lis 2025, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

4 lis 2025, 23:30 UTC

Earnings

Itau Unibanco 3Q Net BRL33.7B >ITUB

4 lis 2025, 23:25 UTC

Earnings

Naver 3Q Net Profit Beat FactSet-Compiled Consensus

4 lis 2025, 23:25 UTC

Earnings

Naver 3Q Net KRW734.70B Vs. Net KRW530.10B >035420.SE

4 lis 2025, 23:24 UTC

Earnings

Naver 3Q Oper Pft KRW570.60B Vs. Pft KRW525.30B >035420.SE

4 lis 2025, 23:23 UTC

Earnings

Naver 3Q Rev KRW3.138T Vs. KRW2.716T >035420.SE

4 lis 2025, 23:06 UTC

Earnings

Review & Preview: Tech Check -- Barrons.com

4 lis 2025, 22:52 UTC

Earnings

AMD Reports Sharply Higher Profits, Sales -- 3rd Update

4 lis 2025, 22:33 UTC

Earnings

AMD Beats Earnings. The Stock Still Slides. -- Barrons.com

4 lis 2025, 22:29 UTC

Earnings

Ashland 4Q Adj EPS $1.08 >ASH

4 lis 2025, 22:29 UTC

Earnings

Ashland Sees FY26 Adjusted EPS Up More Than Double Digits >ASH

4 lis 2025, 22:28 UTC

Earnings

Ashland Sees FY26 Sales $1.84B-$1.91B >ASH

4 lis 2025, 22:27 UTC

Earnings

Ashland 4Q Cont Ops EPS 73c >ASH

4 lis 2025, 22:27 UTC

Earnings

Ashland 4Q EPS 71c >ASH

4 lis 2025, 22:27 UTC

Earnings

Ashland 4Q Sales $478M >ASH

4 lis 2025, 22:23 UTC

Earnings

Ovintiv 3Q EPS 57c >OVV

4 lis 2025, 22:19 UTC

Market Talk

Canada Budget: Snap Election Talk Might Cool -- Market Talk

4 lis 2025, 22:16 UTC

Earnings

AMD Reports Sharply Higher Profits, Sales -- 2nd Update

4 lis 2025, 22:14 UTC

Acquisitions, Mergers, Takeovers

Kennedy-Wilson Board Forms Special Committee to Evaluate Proposal

4 lis 2025, 22:13 UTC

Acquisitions, Mergers, Takeovers

Consortium: Not Interested in Selling Kennedy-Wilson Shares to Another Party

4 lis 2025, 22:13 UTC

Acquisitions, Mergers, Takeovers

Consortium: Able to Finance a Deal With Available Liquidity

4 lis 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

Consortium Owns About 31% of Kennedy-Wilson Stock on As-Converted Basis

4 lis 2025, 22:11 UTC

Earnings

Private-Credit Earnings Ease Investor Concern Over Market's Health -- Update

4 lis 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

Kennedy-Wilson Gets Proposal From CEO William McMorrow and Fairfax Financial Holdings

4 lis 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4 lis 2025, 22:07 UTC

Earnings

Kinross Gold Raises Dividend to $0.035 >K.T

Peer Comparison

Price change

Palvella Therapeutics Inc Forecast

Price Target

By TipRanks

19.54% upside

12 Months Forecast

Average 89.73 USD  19.54%

High 200 USD

Low 54 USD

Based on 11 Wall Street analysts offering 12 month price targets forPalvella Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

11

Buy

0

Hold

0

Sell

Sentiment

By Acuity

117 / 373 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

$

help-icon Live chat